Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to
confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized
Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of
0.3 mg/kg zilucoplan or placebo for 12 weeks.